sEVs from tonsil-derived mesenchymal stromal cells alleviate activation of hepatic stellate cells and liver fibrosis through miR-486-5p
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Mesenchymal stromal cells (MSCs) are considered as a promising therapeutic tool for liver fibrosis, a main feature of chronic liver disease. Because small extracellular vesicles (sEVs) harboring a variety of proteins and RNAs are known to have similar functions with their derived cells, MSC-derived sEVs carry out the regenerative capacities of MSCs. Human tonsil-derived MSCs (T-MSCs) are reported as a novel source of MSCs, but their effects on liver fibrosis remain unclear. In the present study, we investigated the effects of T-MSC-derived sEVs on liver fibrosis. The expression of profibrotic genes decreased in human primary hepatic stellate cells (pHSCs) co-cultured with T-MSCs. Treatment of T-MSC-sEVs inactivated human and mouse pHSCs. Administration of T-MSC-sEVs ameliorated hepatic injuries and fibrosis in chronically damaged liver induced by carbon tetrachloride (CCl 4 ). miR-486-5p highly enriched in T-MSC-sEVs targeting the hedgehog receptor, smoothened (Smo), was upregulated, whereas Smo and Gli2, the hedgehog target gene, were downregulated in pHSCs and liver tissues treated with T-MSC-sEVs or miR-486-5p mimic, indicating that sEV-miR-486 inactivates HSCs by suppressing hedgehog signaling. Our results showed that T-MSCs attenuate HSC activation and liver fibrosis by delivering sEVs, and miR-486 in the sEVs inactivates hedgehog signaling, suggesting that T-MSCs and their sEVs are novel anti-fibrotic therapeutics for treating chronic liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Concise review: MSC-derived exosomes for cell-free therapy
Phinney, D. G., & Pittenger, M. F. (2017) · Stem Cells · doi:10.1002/stem.2575 · Cited by 1,834
Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine
Vizoso, F., Eiro, N., Cid, S., Schneider, J., & Perez-Fernandez, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091852 · Cited by 1,363 · cited 1×
“Growing evidence indicates that the therapeutic effects of MSC therapy are mediated by secretory factors that MSCs produce and release, and these secretory factors are called the MSC secretome.(34) Because sEVs are a part of the MSC secretome, it has been reported that sEVs released from MSCs are highly involved in th…”
BackgroundHa, D., Yang, N., & Nadithe, V. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.02.001 · Cited by 1,346
An, S. Y., Jang, Y. J., Lim, H.-J., Han, J., Lee, J., Lee, G., Park, J. Y., Park, S.-Y., Kim, J. H., Do, B.-R., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.003 · Cited by 193
Self-citationHuang, B., Cheng, X., Wang, H., Huang, W., la Ga hu, Z., Wang, D., Zhang, K., Zhang, H., Xue, Z., Da, Y., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0792-1 · Cited by 183
Cited by
Kou, M., Huang, L., Yang, J., Chiang, Z., Chen, S., Liu, J., Guo, L., Zhang, X., Zhou, X., Xu, X., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05034-x · Cited by 640
Huc-MSC-derived exosomes modified with the targeting peptide of aHSCs for liver fibrosis therapy
Lin, Y., Yan, M., Bai, Z., Xie, Y., Ren, L., Wei, J., Zhu, D., Wang, H., Liu, Y., Luo, J., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01636-x · Cited by 125
“MSC-derived exosomes retain similar molecular cargo similar to that of parent MSCs, which can also significantly decrease the activation of HSCs [17, 18].”
BackgroundMesenchymal stromal cells in hepatic fibrosis/cirrhosis: from pathogenesis to treatment
Yang, X., Li, Q., Liu, W., Zong, C., Wei, L., Shi, Y., & Han, Z. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-00983-5 · Cited by 120
Mesenchymal Stem Cell–Derived Exosomes in Various Chronic Liver Diseases: Hype or Hope?
Zhu, L., Wang, Q., Guo, M., Fang, H., Li, T., Zhu, Y., Jiang, H., Xiao, P., & Hu, M. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s439974 · Cited by 21
“127,128,133 Suppressing the excessive proliferation of hepatic stellate cells and the over-deposition of collagen is an important mechanism for the anti-fibrotic effects of MSC-EVs.”
BackgroundZhu, D., Sun, Z., Wei, J., Zhang, Y., An, W., Lin, Y., & Li, X. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s450284 · Cited by 17
“41 42–44 However, their effect on anti-liver fibrosis is limited.”
Background
Metadata
- Authors
- Kim, J., Lee, C., Shin, Y., Wang, S., Han, J., Kim, M., Kim, J. M., Shin, S.-C., Lee, B.-J., Kim, T.-J., & Jung, Y.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 29
- Issue
- 4
- Pages
- 1471-1486
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W3116612182
- Cited by
- 69
- References
- 7
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.